Molecular pathogenesis of malignant mesothelioma.

Philip A. Rascoe, Daniel Jupiter, Xiaobo Cao, James E. Littlejohn, W. Roy Smythe

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Malignant mesothelioma is a rare, highly aggressive cancer arising from mesothelial cells that line the pleural cavities. Approximately 80% of mesothelioma cases can be directly attributed to asbestos exposure. Additional suspected causes or co-carcinogens include other mineral fibres, simian virus 40 (SV40) and radiation. A mesothelioma epidemic in Turkey has demonstrated a probable genetic predisposition to mineral fibre carcinogenesis and studies of human tissues and animal models of mesothelioma have demonstrated genetic and epigenetic events that contribute to the multistep process of mineral fibre carcinogenesis. Several growth factors and their receptors have a significant role in the oncogenesis, progression and resistance to therapy of mesothelioma. Epidermal growth factor (EGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF) have been shown as targets for therapy based on promising preclinical data. However, clinical trials of tyrosine kinase inhibitors in mesothelioma have been disappointing. Bcl-XL is an important antiapoptotic member of the Bcl-2 family and is overexpressed in several solid tumours, including mesothelioma. Reduction of Bcl-XL expression in mesothelioma induces apoptosis and engenders sensitisation to cytotoxic chemotherapeutic agents. Pharmacological inhibitors of antiapoptotic Bcl-2 family members continue to undergo refinement and have shown promise in mesothelioma.

Original languageEnglish (US)
JournalExpert Reviews in Molecular Medicine
Volume14
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Mesothelioma
Mineral Fibers
Carcinogenesis
Pleural Cavity
Simian virus 40
Hepatocyte Growth Factor
Growth Factor Receptors
Malignant Mesothelioma
Asbestos
Cytotoxins
Somatomedins
Genetic Predisposition to Disease
Turkey
Epidermal Growth Factor
Epigenomics
Carcinogens
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Neoplasms
Animal Models

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Molecular pathogenesis of malignant mesothelioma. / Rascoe, Philip A.; Jupiter, Daniel; Cao, Xiaobo; Littlejohn, James E.; Smythe, W. Roy.

In: Expert Reviews in Molecular Medicine, Vol. 14, 2012.

Research output: Contribution to journalArticle

Rascoe, Philip A. ; Jupiter, Daniel ; Cao, Xiaobo ; Littlejohn, James E. ; Smythe, W. Roy. / Molecular pathogenesis of malignant mesothelioma. In: Expert Reviews in Molecular Medicine. 2012 ; Vol. 14.
@article{0bf686010eac49d9b291ec6075645e0d,
title = "Molecular pathogenesis of malignant mesothelioma.",
abstract = "Malignant mesothelioma is a rare, highly aggressive cancer arising from mesothelial cells that line the pleural cavities. Approximately 80{\%} of mesothelioma cases can be directly attributed to asbestos exposure. Additional suspected causes or co-carcinogens include other mineral fibres, simian virus 40 (SV40) and radiation. A mesothelioma epidemic in Turkey has demonstrated a probable genetic predisposition to mineral fibre carcinogenesis and studies of human tissues and animal models of mesothelioma have demonstrated genetic and epigenetic events that contribute to the multistep process of mineral fibre carcinogenesis. Several growth factors and their receptors have a significant role in the oncogenesis, progression and resistance to therapy of mesothelioma. Epidermal growth factor (EGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF) have been shown as targets for therapy based on promising preclinical data. However, clinical trials of tyrosine kinase inhibitors in mesothelioma have been disappointing. Bcl-XL is an important antiapoptotic member of the Bcl-2 family and is overexpressed in several solid tumours, including mesothelioma. Reduction of Bcl-XL expression in mesothelioma induces apoptosis and engenders sensitisation to cytotoxic chemotherapeutic agents. Pharmacological inhibitors of antiapoptotic Bcl-2 family members continue to undergo refinement and have shown promise in mesothelioma.",
author = "Rascoe, {Philip A.} and Daniel Jupiter and Xiaobo Cao and Littlejohn, {James E.} and Smythe, {W. Roy}",
year = "2012",
doi = "10.1017/erm.2012.6",
language = "English (US)",
volume = "14",
journal = "Expert Reviews in Molecular Medicine",
issn = "1462-3994",
publisher = "Cambridge University Press",

}

TY - JOUR

T1 - Molecular pathogenesis of malignant mesothelioma.

AU - Rascoe, Philip A.

AU - Jupiter, Daniel

AU - Cao, Xiaobo

AU - Littlejohn, James E.

AU - Smythe, W. Roy

PY - 2012

Y1 - 2012

N2 - Malignant mesothelioma is a rare, highly aggressive cancer arising from mesothelial cells that line the pleural cavities. Approximately 80% of mesothelioma cases can be directly attributed to asbestos exposure. Additional suspected causes or co-carcinogens include other mineral fibres, simian virus 40 (SV40) and radiation. A mesothelioma epidemic in Turkey has demonstrated a probable genetic predisposition to mineral fibre carcinogenesis and studies of human tissues and animal models of mesothelioma have demonstrated genetic and epigenetic events that contribute to the multistep process of mineral fibre carcinogenesis. Several growth factors and their receptors have a significant role in the oncogenesis, progression and resistance to therapy of mesothelioma. Epidermal growth factor (EGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF) have been shown as targets for therapy based on promising preclinical data. However, clinical trials of tyrosine kinase inhibitors in mesothelioma have been disappointing. Bcl-XL is an important antiapoptotic member of the Bcl-2 family and is overexpressed in several solid tumours, including mesothelioma. Reduction of Bcl-XL expression in mesothelioma induces apoptosis and engenders sensitisation to cytotoxic chemotherapeutic agents. Pharmacological inhibitors of antiapoptotic Bcl-2 family members continue to undergo refinement and have shown promise in mesothelioma.

AB - Malignant mesothelioma is a rare, highly aggressive cancer arising from mesothelial cells that line the pleural cavities. Approximately 80% of mesothelioma cases can be directly attributed to asbestos exposure. Additional suspected causes or co-carcinogens include other mineral fibres, simian virus 40 (SV40) and radiation. A mesothelioma epidemic in Turkey has demonstrated a probable genetic predisposition to mineral fibre carcinogenesis and studies of human tissues and animal models of mesothelioma have demonstrated genetic and epigenetic events that contribute to the multistep process of mineral fibre carcinogenesis. Several growth factors and their receptors have a significant role in the oncogenesis, progression and resistance to therapy of mesothelioma. Epidermal growth factor (EGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF) have been shown as targets for therapy based on promising preclinical data. However, clinical trials of tyrosine kinase inhibitors in mesothelioma have been disappointing. Bcl-XL is an important antiapoptotic member of the Bcl-2 family and is overexpressed in several solid tumours, including mesothelioma. Reduction of Bcl-XL expression in mesothelioma induces apoptosis and engenders sensitisation to cytotoxic chemotherapeutic agents. Pharmacological inhibitors of antiapoptotic Bcl-2 family members continue to undergo refinement and have shown promise in mesothelioma.

UR - http://www.scopus.com/inward/record.url?scp=84866178017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866178017&partnerID=8YFLogxK

U2 - 10.1017/erm.2012.6

DO - 10.1017/erm.2012.6

M3 - Article

VL - 14

JO - Expert Reviews in Molecular Medicine

JF - Expert Reviews in Molecular Medicine

SN - 1462-3994

ER -